Here are the 10-Q quarterly reports from ADMA Biologics, Inc. (ADMA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ADMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADMA filings page.
ADMA Biologics, Inc. reported third-quarter 2026 revenue of $141.102 million, versus $134.224 million a year earlier, and net income of $49.884 million, versus $36.428 million. ASCENIV revenue was $124.742 million, compared with $95.410 million; diluted earnings per share were $0.22, versus $0.15.
For the first nine months, net income was $133.034 million, versus $97.551 million in 2025, while operating cash flow was $105.156 million, versus $14.757 million. Cash was $124.555 million at September 30, 2026. ADMA sold three plasma centers for $12.0 million and recognized an approximately $8.0 million gain.
ADMA borrowed $125.0 million under the JPMorgan revolving facility to fund an accelerated share repurchase; treasury-stock acquisitions used $180.300 million in nine-month financing cash flow. Total debt was $195.857 million at September 30, 2026, versus $72.143 million at December 31, 2025. For SG-001, ADMA said the FDA gave constructive feedback in October 2026 on the pre-IND package; the agency said the proposed assay would be acceptable subject to appropriate validation, and ADMA plans to incorporate recommendations into its clinical protocol.
ADMA Biologics reported strong profitability on flat revenue for the quarter ended March 31, 2026. Total revenue was $114.5 million, essentially unchanged year over year, but product mix shifted sharply. ASCENIV sales rose to $97.5 million, up 27.7%, while other IVIG and intermediates declined.
Gross profit increased to $80.8 million and gross margin expanded significantly, helped by ASCENIV growth and the new yield‑enhanced manufacturing process. Net income rose to $45.3 million, compared with $26.9 million a year earlier, with diluted EPS of $0.19.
ADMA used leverage to fund capital returns. It drew $125.0 million on its JPM revolving facility and repurchased 6.8 million shares for $111.1 million, including an accelerated share repurchase. Cash ended at $138.2 million, while total debt increased to $196.9 million.
The company also sold three plasma centers for $12.0 million, recognizing about $8.0 million gain, and later obtained FDA approval to expand ASCENIV’s label to children two years and older.
ADMA Biologics reported solid Q3 results, reflecting continued demand for its immunoglobulin portfolio. Revenue reached $134.224 million, up from $119.839 million a year ago, with net income of $36.428 million and diluted EPS of $0.15. Gross profit was $75.626 million, and income from operations rose to $51.012 million.
On the balance sheet, cash and equivalents were $61.385 million and total assets were $568.687 million as of September 30, 2025. Long-term debt stood at $70.084 million. The company refinanced with a new JPMorgan facility, drawing a $75 million term loan and establishing a $225 million revolver; the term loan rate was approximately 6.75% at quarter-end.
ADMA authorized a share repurchase program of up to $500.0 million and repurchased 1.329 million shares for $23.188 million year-to-date. The FDA approved an ASCENIV/BIVIGAM process PAS in April 2025 that has started to increase bulk yields; the company states it believes this should drive revenue and earnings accretion beginning in Q4 2025. ADMA also acquired Boca Raton real estate for $12.6 million to support expanded operations.